Skip to main content

Hepatocellular Cancer clinical trials at UCSF
1 in progress, 1 open to new patients

  • AFPᶜ³³²T in Advanced HCC

    open to eligible people ages 18–75

    This study will investigate the safety and tolerability of AFPᶜ³³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker, whose liver tumor has the AFP protein and whose noncancerous liver tissue has very little AFP protein. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors.

    San Francisco, California and other locations